Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus XELOX in locally advanced gastric adenocarcinoma
NCT03599778Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Sep 2018
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in gastric adenocarcinoma, sponsored by The First Affiliated Hospital of USTC. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03599778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03599778.